Peer Reviewed
Drug update

Rivastigmine transdermal patch for mild to moderately severe Alzheimer’s disease

Gideon Caplan, Lisa Kelly
Abstract
Rivastigmine transdermal formulation (Exelon Patch) demonstrates a significantly lower incidence of gastrointestinal side effects in trials to date and may help with compliance to medication in certain groups of patients with Alzheimer’s disease.
Key Points

    Alzheimer’s disease accounts for approximately 70% of dementias worldwide. In Australia, the percentage of the population with dementia increased to 1% in 2005. Unfortunately there is currently no cure for dementia, but pharmacological treatment for Alzheimer’s disease has been available for over 10 years Although the effect of treatment is only mild on average, some patients respond more clearly than others. Treatment can make a significant difference for many people with dementia as well as their carers.

Get full access
Subscribe for full access to all articles
Buy this article

Single article purchases are temporarily unavailable due to site maintenance.

If you would like to purchase an article during this time, please email us at [email protected] with the article details and we'll assist you directly. We'll also let you know when online purchasing is available again.

Thank you for your patience and understanding.

Already a subscriber?